315 results match your criteria: "IRCCS Azienda Ospedaliera Universitaria San Martino - IST[Affiliation]"
Eur J Intern Med
December 2024
Unit of Internal Medicine, Scientific Institute "Casa Sollievo della Sofferenza", San Giovanni Rotondo, FG, Italy.
Methods Mol Biol
August 2023
UO Pediatria 2, Istituto G. Gaslini, Genova, Italy.
Tumori
June 2023
Division of Cancer Control and Population Sciences, Outcomes Research Branch, National Cancer Institute, Rockville, Maryland, USA.
Introduction: US National Cancer Institute's (NCI) Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a library of 78 symptom terms and 124 items enabling patient reporting of symptomatic adverse events in cancer trials. This multicenter study used mixed methods to develop an Italian language version of this widely accepted measure, and describe the content validity and reliability in a diverse sample of Italian-speaking patients.
Methods: All PRO-CTCAE items were translated in accordance with international guidelines.
BMC Med
January 2022
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Background: Cabazitaxel improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients progressing after docetaxel. In this prospective study, we evaluated the prognostic role of CTC gene expression on cabazitaxel-treated patients and its association with plasma androgen receptor (AR) copy number (CN).
Methods: Patients receiving cabazitaxel 20 or 25 mg/sqm for mCRPC were enrolled.
Ther Adv Urol
October 2021
Division of Oncology, AOU Consorziale Policlinico di Bari, Bari, Italy.
Background: Considering the growing genitourinary (GU) cancer population undergoing systemic treatment with immune checkpoint inhibitors (ICIs) in the context of the COVID-19 pandemic, we planned a clinical audit in 24 Italian institutions treating GU malignancies.
Objective: The primary objective was investigating the clinical impact of COVID-19 in GU cancer patients undergoing ICI-based therapy during the first outbreak of SARS-CoV-2 contagion in Italy.
Design Setting And Participants: The included centers were 24 Oncology Departments.
Am J Clin Oncol
March 2021
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
Objectives: The aim of our study was to collect data about of the outcome of metastatic renal cell carcinoma patients who progressed after immune checkpoint inhibitors in order to enhance data about efficacy and safety of treatment beyond immune-oncology (IO).
Materials And Methods: A total of 162 eligible patients, progressing to IO, were enrolled from 16 Italian referral centers adhering to the Meet-Uro association. Baseline characteristics, outcome data and toxicities were retrospectively collected.
Am J Blood Res
December 2020
Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena Italy.
Introduction: Mantle-cell lymphoma (MCL) with relapsed/refractory (R/R) disease after intensive chemotherapy have few effective treatment options. Ibrutinib showed a promising median progression-free survival (PFS) with manageable toxicity. The BCL2 inhibitor venetoclax showed encouraging results in R/R MCL patients and preclinical models suggest a potential synergistic effect of dual BTK and BCL2 inhibition.
View Article and Find Full Text PDFEur Spine J
January 2021
School of Medicine, Department of Basic Medical Sciences, Neuroscience and Sense Organs, Orthopaedic, Trauma and Spine Unit, University of Bari "Aldo Moro"-AOU Policlinico Consorziale, Bari, Italy.
Eur Spine J
January 2021
School of Medicine, Department of Basic Medical Sciences, Neuroscience and Sense Organs, Orthopaedic, Trauma and Spine Unit, University of Bari "Aldo Moro"-AOU Policlinico Consorziale, Bari, Italy.
Ann Oncol
October 2020
Medical Oncology Department, University of Torino, San Luigi Hospital, Orbassano, Italy.
Purpose: The retinal rod outer segment (OS) disk membranes, devoid of mitochondria, conducts oxidative phosphorylation (OxPhos). This study aimed at identifying which proteins expressed in the retinal rod OS disks determined the considerable adenosine-5'-triphosphate production and oxygen consumption observed in comparison with retinal mitochondria.
Procedures: Characterization was conducted by immunogold transmission electron microscopy on retinal sections.
Eur J Intern Med
October 2019
Scientific Direction, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Clin Genitourin Cancer
August 2019
Medical Oncology Department, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. Electronic address:
Background: Cabozantinib showed efficacy and manageable toxicity in patients with metastatic renal cell carcinoma (mRCC). In this study we aimed to describe the safety and to collect evidence on the potential efficacy of cabozantinib in mRCC patients with brain metastases (BM) in a real-world experience.
Materials And Methods: We retrospectively collected data of patients treated with cabozantinib within the Italian Managed Access Program.
Liver Int
August 2019
Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Background: The Italian Liver Cancer (ITA.LI.CA) prognostic system for patients with hepatocellular carcinoma (HCC) has recently been proposed and validated.
View Article and Find Full Text PDFSemin Oncol
April 2019
Division of Medical Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Italy; Cellular Therapy and Immunobiology Working Party, EBMT.
Backgroud: Germ cell tumors (GCTs) are a group of neoplasms usually arising in the gonads, and very rarely in sites outside the gonads, mainly in the retroperitoneum, the anterior mediastinum, and pineal gland or the coccyx (mainly in childhood). The prognosis of nonseminoma primary mediastinal GCTs (PMGCTs), is considered to be poorer compared to its retroperitoneal or gonadal counterparts and, according to the International Germ Cell Cancer Collaborative Group, it is considered by definition as a "poor risk" disease.
Material And Methods: Our review highlights the clinical features, prognostic factors, and therapeutic strategies in PMGCTs, as described in medical literature.
Urol Oncol
August 2019
Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Objectives: To investigate if a first-line treatment delay (TD) can negatively affect the outcomes of patients affected by metastatic renal cancer.
Patients And Methods: Patients with a diagnosis of metastatic renal cancer who were ineligible for active surveillance were included in the sample. A TD was defined as the time from the diagnosis of metastatic disease to the start of first-line therapy with tyrosine kinase inhibitors.
Hypertens Res
August 2019
School of Medicine and Surgery, University Milano, Bicocca, Milan, Italy.
The aim of this study was to investigate the relationship between endothelin-1, nitric oxide, insulin resistance, and blood pressure in young subjects with a high prevalence of excess weight and/or elevated blood pressure. In a cohort of 238 children (mean age = 11.1 years), height, weight, waist circumference, and blood pressure were assessed.
View Article and Find Full Text PDFDiabetes Care
April 2019
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL). The aim of this analysis is to report long-term outcome and toxicities in newly diagnosed DLBCL patients who received R2-CHOP21 in two independent phase 2 trials, conducted by Mayo Clinic (MC) and Fondazione Italiana Linfomi (FIL). All patients received R-CHOP21 plus lenalidomide.
View Article and Find Full Text PDFTher Clin Risk Manag
September 2018
Department of Experimental Neurology, IRCCS Centro Neurolesi "Bonino Pulejo", Messina, Italy,
Purpose: We performed a pharmacovigilance study of 10 drugs used in patients with relapsing-remitting multiple sclerosis (RR-MS). Our aim was to provide an overview of the safety of these drugs by the evaluation of reported expected and unexpected adverse reactions.
Patients And Methods: We collected and analyzed adverse drug reactions from RR-MS patients belonging to four hospitals in three Italian regions, for a period of 24 months.
Am J Clin Oncol
January 2019
Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan.
Objective: The activity of cabozantinib in nonclear cell histologies has not been evaluated.
Materials And Methods: Data were collected across 24 Italian hospitals. Patients were aged 18 years and older with advanced nonclear cell renal cell carcinoma (RCC), with an Eastern Cooperative Oncology Group Performance Status 0 to 2, who had relapsed after previous systemic treatments for metastatic disease.
Crit Rev Oncol Hematol
October 2018
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. Electronic address:
Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10% with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity.
View Article and Find Full Text PDFLancet Gastroenterol Hepatol
September 2018
Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK.
Background: Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after 12 months are subsequently considered for second-line therapies. However, as a result, patients at the highest risk can wait the longest for effective treatment. We determined whether UDCA response can be accurately predicted using pretreatment clinical parameters.
View Article and Find Full Text PDFCancer Treat Rev
July 2018
Clinical Medicine and Surgery Department, University of Naples Federico II, 80131 Naples, Italy. Electronic address:
Triple negative breast cancer (TNBC) represents the 15-20% of all breast cancers (BC) and is characterized by a very aggressive behavior. Recent data suggest that TNBC is not a single disease, but it is rather an umbrella for different ontology-profiles such as basal like 1 and 2, mesenchymal, and the luminal androgen receptor (LAR). The LAR subtype is characterized by the expression of the Androgen Receptor (AR) and its downstream effects.
View Article and Find Full Text PDF